Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).
about
New, improved treatments for Chagas disease: from the R&D pipeline to the patientsChagas disease: "the new HIV/AIDS of the Americas"Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection)Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up StudiesTreatment of Chagas cardiomyopathyTolerance of benznidazole in treatment of Chagas' disease in adultsImproved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural BoliviaPopulation pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adultsHigh throughput screening for anti-Trypanosoma cruzi drug discoveryTen-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donorsMulticenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain.Chagas cardiomyopathy manifestations and Trypanosoma cruzi genotypes circulating in chronic Chagasic patients.Cardiac involvement with parasitic infections.A Latin American man with palpitations, dizziness, episodes of nonsustained ventricular tachycardia, and an apical aneurysmNitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' diseaseGastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis.Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.Current and developing therapeutic agents in the treatment of Chagas diseaseChagas disease. What is known and what should be improved: a systemic review.Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection.Benznidazole shortage makes chagas disease a neglected tropical disease in developed countries: data from SpainMyocardial chemokine expression and intensity of myocarditis in Chagas cardiomyopathy are controlled by polymorphisms in CXCL9 and CXCL10.Prevalence of Trypanosoma cruzi infection among people aged 15 to 89 years inhabiting the Department of Casanare (Colombia)Genetic dissection of drug resistance in trypanosomesExperimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones.Characterization of an immunodominant antigenic epitope from Trypanosoma cruzi as a biomarker of chronic Chagas' disease pathology.Integrated control of Chagas disease for its elimination as public health problem--a reviewLimited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.Therapy of chagas disease: implications for levels of prevention.Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response.Enteric Neuronal Damage, Intramuscular Denervation and Smooth Muscle Phenotype Changes as Mechanisms of Chagasic Megacolon: Evidence from a Long-Term Murine Model of Trypanosoma cruzi InfectionEmerging and under-recognized Chagas cardiomyopathy in non-endemic countriesEnalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi.Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.Challenge of chronically infected mice with homologous trypanosoma cruzi parasites enhances the immune response but does not modify cardiopathy: implications for the design of a therapeutic vaccine.Heart failure in South America.Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospectsA scientometric evaluation of the Chagas disease implementation research programme of the PAHO and TDR.Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.Towards a paradigm shift in the treatment of chronic Chagas disease.
P2860
Q21092295-F457166D-F349-4B76-84AD-B1B31C595D1CQ21144502-ECFAB43F-87D2-4391-8CC9-86F0D0EDE4ECQ24245957-28E2E01D-0555-4457-BCF3-31DE853426D8Q26782118-1912DAC7-0A04-413F-B5B6-89082B570054Q26829616-8F860F39-D139-43E5-80C2-EAAB04451CDFQ28292605-CC42C81F-9CB4-4706-B8F4-F1CD88FAC86BQ28533625-674EB603-A0EB-4038-98B1-78C210163D24Q28539049-D4E2B948-6B90-46E7-80BF-5739D36F125AQ28542489-6A700ACA-4B52-475B-9069-68BB29D4BAC5Q30441765-301A9B25-A312-4A8A-A0CA-59BF9C01EDC0Q33162074-F558416C-48D6-4154-A5B5-EA0CB5D88B92Q33769907-E8A959AD-27D7-4C69-A1D8-5A8ABF3CCD75Q33825602-DB924886-F7CB-45C4-B483-2413269F16ABQ33834042-17D63E2F-CC80-42FB-8951-BEF82A6D4499Q33870409-DD5E6CA9-554D-4D1B-A2AE-9DC65F3A360BQ33873600-791B4552-156A-46D2-B403-4BABEF45F256Q33975717-C29BACDD-9398-4A4B-B9E6-B877C9D33F96Q34170132-532CBD08-0895-4EFD-BC51-E4E9B2C2F655Q34285817-00735FFC-FDAD-420A-A313-A16AA6521D2AQ34310471-68F5B46A-A32D-41DC-8B9B-05D864A12080Q34349229-11721A46-0146-41F4-9844-58A388242DBAQ34476397-E7DC9DF3-CFCD-4F24-98A3-4F4162170A66Q34626145-540395FA-082D-44B8-B627-B06E6E5B0572Q34647009-038C26FC-E080-41EA-9C8A-89F85A6C8121Q35367533-4EC0AF05-3F37-4133-9664-EA6219A1AECAQ35739066-13B5B127-E57E-4136-AC53-1D11571BDC27Q35810731-DEEB8669-32B8-4ED5-AB64-EEDD03F78ADFQ35859935-BC290D3A-5C0C-4760-A109-B0713ABC9271Q35864834-EB80A25C-79F4-458F-A352-5719FAF5A695Q35883877-01022E91-0211-4B7A-9D46-32A9C78E668DQ35979730-66DF69E0-E3C6-4BE3-9B11-DE6B2D695266Q36170517-D443D53C-F6FB-43DB-A4C7-D9B6C916F300Q36436221-C2B505E8-C36F-4051-BCE6-2B8EB71DB409Q36505372-5ED28DFA-DF63-438D-AA47-81454C451919Q36606779-825D1671-944F-4877-AA0C-4936A4BC1FE5Q36928523-2C30E4C9-5C31-42B0-9446-147779068456Q37286061-879B30B0-8E0F-4DFD-A8A3-096072A15D4EQ37288871-B6880F4F-CC04-4B97-9F65-9ACDB8703B09Q37309281-B18C91A5-45ED-435C-A566-F206C844E413Q37544885-549EAC52-CB49-46AF-B122-6C1B103BE977
P2860
Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Rationale and design of a rand ...... ing Trypanosomiasis (BENEFIT).
@en
Rationale and design of a rand ...... r Interrupting Trypanosomiasis
@nl
type
label
Rationale and design of a rand ...... ing Trypanosomiasis (BENEFIT).
@en
Rationale and design of a rand ...... r Interrupting Trypanosomiasis
@nl
prefLabel
Rationale and design of a rand ...... ing Trypanosomiasis (BENEFIT).
@en
Rationale and design of a rand ...... r Interrupting Trypanosomiasis
@nl
P2093
P921
P1476
Rationale and design of a rand ...... ing Trypanosomiasis (BENEFIT).
@en
P2093
Alvaro Avezum
Anis Rassi
BENEFIT Investigators
Carlos A Morillo
Fernando Rosas
Jose Antonio Marin-Neto
Stuart J Connolly
P356
10.1016/J.AHJ.2008.04.001
P407
P577
2008-07-01T00:00:00Z